Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
复制标题
DOI：
10.1093/annonc/mds195
复制
发表时间：
2012-08-01
影响因子：
50.5
通讯作者：
Zielinski, C. C.
中科院分区：
文献类型：
--
作者：
Andre, F.;Zielinski, C. C.
三阴性乳腺癌（TNBC）是一种侵袭性组织学亚型，治疗选择有限，标准化疗方案后进展后预后极差。对当前标准疗法如蒽环类或紫杉烷类的抗性将先前治疗的转移性TNBC患者的可用选择限制为少量非交叉抗性方案，并且目前没有优选的标准化疗。反应持续时间通常很短，快速复发非常常见，中位生存期仅为13个月。新批准的药物艾日布林在既往接受过含蒽环类或紫杉烷方案治疗的患者中显示出生存获益，包括TNBC患者。铂类药物治疗方案是BRCA1突变患者的新兴选择，新的靶向药物如贝伐单抗血管生成治疗或西妥昔单抗表皮生长因子受体治疗在联合治疗中显示出一定的获益。然而，对于用于该患者群体的改进的靶向剂仍然存在迫切的未满足的需求。生物标志物引导的亚组分子靶点的理解可能有助于改善治疗，这可能预测目前批准的药物以及更新的靶向药物的益处。
Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy. Duration of response is usually short, with rapid relapse very common and median survival of just 13 months. The newly approved agent eribulin has shown a survival benefit in patients who had previously been treated with anthracycline- or taxane-containing regimens, including in patients with TNBC. Platinum-based regimens are an emerging option for patients with BRCA1 mutation, and newer targeted agents such as anti-angiogenic treatment with bevacizumab or anti-epidermal growth factor receptor treatment with cetuximab, have shown some benefit in combination therapy. However, there remains an urgent unmet need for improved targeted agents for this patient population. Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs.